Performance & Growth Peptides
Growth hormone secretagogues and performance-related peptides studied for their effects on GH release, muscle protein synthesis, and body composition in clinical research.
This section covers peptides that stimulate growth hormone release through various receptor pathways. These compounds are primarily studied in the context of growth hormone deficiency, sarcopenia, and age-related decline in GH secretion.
Evidence Note: Several GH secretagogues have Phase 1-2 clinical data. Sermorelin has historical FDA approval (since withdrawn). None are currently FDA-approved for performance enhancement. WADA bans most GH secretagogues.
Ipamorelin
Evidence Tier: Phase 1-2 Clinical Data — Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist. It stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels.
CJC-1295 (with and without DAC)
Evidence Tier: Phase 1-2 (development discontinued) — CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with enhanced half-life. The DAC (Drug Affinity Complex) variant binds to albumin for extended duration.
GHRP-2 (Growth Hormone Releasing Peptide-2)
Evidence Tier: Phase 1-2 Clinical Data — GHRP-2 (pralmorelin) is a synthetic hexapeptide GH secretagogue that acts on the ghrelin receptor. Approved in Japan as a diagnostic agent for GH deficiency.